Skip to main content
Clinical Trials/NCT00307775
NCT00307775
Terminated
Not Applicable

A Pilot Study to Examine the Efficacy of Vaginally Administered Oestradiol in the Treatment of Faecal Incontinence in Post Menopausal Women

London North West Healthcare NHS Trust1 site in 1 country43 target enrollmentMarch 2006

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Fecal Incontinence
Sponsor
London North West Healthcare NHS Trust
Enrollment
43
Locations
1
Primary Endpoint
Improvement of symptoms and quality of life (QoL) as measured by QoL questionnaires and physiological assessment
Status
Terminated
Last Updated
14 years ago

Overview

Brief Summary

This study will address the following questions:

  • Does the use of oestrogen inserted vaginally with an applicator, help with the symptoms of faecal (bowel) incontinence in women who are past the age of menopause?
  • Do women find it easy to use?
  • Is the treatment safe for the womb lining?
  • Is there any systemic absorption of the treatment?

Detailed Description

Faecal incontinence affects about 5% of women, the most common cause is often cited by women as obstetric trauma. However in clinical practice many women report that their symptoms of faecal incontinence begin around the same time as menopause. A community survey examining the prevalence of faecal incontinence in menopausal women is in progress. If a correlation is found between the onset of menopause and the development of faecal incontinence, further investigation of effective treatment will be indicated. The investigators want to investigate whether vaginally administered oestradiol can alleviate or improve symptoms in women who have faecal incontinence after the menopause. This is a pilot study.

Registry
clinicaltrials.gov
Start Date
March 2006
End Date
October 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Post menopausal women with faecal incontinence

Exclusion Criteria

  • No hormone replacement therapy (HRT) for at least 8 weeks prior to screening
  • Diabetes mellitus
  • Neurological disorder
  • Terminal illness
  • Current treatment for breast cancer
  • Unable to give informed consent

Outcomes

Primary Outcomes

Improvement of symptoms and quality of life (QoL) as measured by QoL questionnaires and physiological assessment

Secondary Outcomes

  • Acceptance of treatment mode delivery, through questionnaire

Study Sites (1)

Loading locations...

Similar Trials